Stocktoria
Evommune, Inc. EVMN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2025-11-06
Chart by TradingView
2/9
Piotroski F — financial health
9.47
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Revenue | $13.0M | $7.0M |
| Operating income | -$81.1M | -$70.0M |
| Net income | -$68.9M | -$66.8M |
| Operating cash flow | -$76.4M | -$58.2M |
| Free cash flow | -$76.7M | -$58.3M |
| Total assets | $224.9M | $76.1M |
| Total liabilities | $19.4M | $28.5M |
| Shareholders' equity | $205.6M | -$144.2M |
| Ratios | ||
| Operating margin | -623.6% | -1000.2% |
| Net margin | -529.8% | -954.4% |
| FCF margin | -589.8% | -832.6% |
| Return on assets | -30.6% | -87.8% |
| Return on equity | -33.5% | 46.3% |
| Current ratio | 8.57 | 2.64 |
| Revenue growth | 85.7% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 36,577 | $840,905 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.47 (safe)
- Working capital / assets 0.603
- Retained earnings / assets -0.983
- EBIT / assets -0.36
- Equity / liabilities 10.607
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002044725 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.